Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta (Q46146766)
Jump to navigation
Jump to search
scientific article published in March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta |
scientific article published in March 2009 |
Statements
1 reference
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta (English)
1 reference
Mar Garcia
1 reference
Jorge E Romaguera
1 reference
Kedar V Inamdar
1 reference
George Z Rassidakis
1 reference
L Jeffrey Medeiros
1 reference
1 March 2009
1 reference
1 reference
115
1 reference
5
1 reference
1041-1048
1 reference
Identifiers
1 reference
1 reference